PCI Pharma Services is a global CDMO with a fifty-year track record of supporting biopharma clients in bringing drug products to market. Headquartered in Philadelphia and operating over 30 GMP sites across North America, Europe, Asia‑Pacific, and Australia, it offers integrated services ranging from early‑stage development to commercial packaging. The company supports approximately 25% of the top 200 drugs and achieves over 90 successful product launches per year. PCI positions itself as a partner of choice for both pharmaceutical and biotechnology clients, combining scientific expertise, robust infrastructure, and advanced technology platforms. It emphasises customer‑centric operations and invests continuously in organic growth, strategic partnerships, and acquisitions to enhance its global reach and service breadth .

Key Products and Services

Development & Manufacturing: Custom formulation and production of small molecules, biologics, and high‑potent compounds, including advanced modalities such as ADCs and targeted therapies.

Clinical Trial Services: Provision of clinical supply services including packaging, global distribution, and analytical support across trial phases.

Sterile & High‑Potent Manufacturing: Expertise in aseptic fill/finish, lyophilisation, and handling of high‑potent compounds with over 35 years of experience.

Advanced Drug Delivery & Combo Products: Design, assembly, testing and packaging of complex drug‑device combination products.

Commercial Packaging: Comprehensive primary and secondary packaging solutions for commercialised pharmaceutical products.

Speed Solutions: pci bridge™, a real‑time supply‑chain platform designed to optimise drug speed‑to‑market.

Analytical & QP Services: Specialized analytical testing, ICH stability support, and Qualified Person services for both sterile and non‑sterile products.

PCI Pharma Services continues to expand its capabilities through strategic investment and facility growth to meet evolving client needs. Supported by recent private‑equity funding valuing the company at around US $10 billion, PCI is accelerating its sterile and high‑potent manufacturing footprint. With a workforce of nearly 8,000 employees and a global site presence, it remains committed to delivering efficient, scalable, and high‑quality contract manufacturing solutions that advance patient access to critical therapies